Story

Novo Nordisk CEO Rejects 'Winner-Take-All' View of Obesity Drug Market

ENTHMSVIIDZHZH-TWJAKOHI
Aug 13, 20262 min read
Novo Nordisk CEO Rejects 'Winner-Take-All' View of Obesity Drug Market
Text size
Background

Novo Nordisk's CEO Mike Doustdar pushed back against investor sentiment that the obesity drug market is a two-horse race, arguing that the sector will become highly segmented with multiple successful products rather than a "winner-take-all" battle with rival Eli Lilly.

In a Wednesday interview with Reuters, Doustdar said the investment community has incorrectly framed the competition as a "zero-sum game," underestimating the demand for differentiated treatments among a massive patient population.

A Differentiated Market

The CEO compared the future of weight-loss drugs to the beverage industry, which supports numerous brands beyond just two dominant players. "It will not be Coke versus Pepsi. It will be Coke and Pepsi and Fanta and Dr Pepper and Red Bull," Doustdar said, according to Reuters. He noted that while all GLP-1 drugs reduce weight, they have different profiles, similar to how Novo's own portfolio of 12 insulin brands all lower blood sugar but serve different patient needs.

This vision counters a market narrative that has seen Novo Nordisk's shares fall from their 2024 peak, while Eli Lilly's stock has continued to climb, pushing its market capitalization above $1 trillion. Novo was first to market with its highly effective injection, Wegovy, but has since faced intense competition from Lilly’s Zepbound in a market analysts project could exceed $100 billion by 2030.

Sample IUX Markets – In-articleAd

Pipeline and Oral Medications

Doustdar highlighted the company's strategy of offering various treatment options, including new oral medications. He stated that Novo's pill version of Wegovy currently holds a 90% share of the oral GLP-1 market. The company sees a significant opportunity in this segment, with the CEO noting Novo is in a "very good place if it becomes a 50-50 market" between pills and injections.

He also addressed investor disappointment regarding the company's next-generation drug, CagriSema, which showed an average weight loss of 23% in trials, compared to over 25% for Zepbound. Despite investors having "written it off," Doustdar defended the drug as a powerful future addition to the company's toolkit, questioning when a doctor has ever had only a single medicine to treat millions of patients.

Read next

More on Stocks
Back to latest news

LATEST